智通财经APP讯，生物股份(600201.SH)发布公告，基于对公司未来持续稳定发展的信心和长期投资价 值的认可，增强投资者信心，公司大股东内蒙古金宇生物控股有限公司(简称"生物控股")计划自公告披 露之日起12个月内，通过上海证券交易所系统以集中竞价方式增持公司股份，增持总金额不低于人民币 5000万元，不超过人民币1亿元。 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2025-062 金宇生物技术股份有限公司 关于大股东增持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 增持主体名称 | 内蒙古金宇生物控股有限公司 | | | | --- | --- | --- | --- | | 增持主体身份 | 控股股东、实控人 | 是 | 否 | | | 控股股东、实控人的一致行动人 | 是 | 否 | | | 直接持股 5%以上股东 | 是 | 否 | | | 董事、监事和高级管理人员 | 是 | 否 | 上述增持主体存在一致行动人： | 股东名称 | 持股数量 （股） | 持股比例 | 一致行动关系形成原因 | | --- | --- | --- | --- | | 内蒙古金宇生 | | | 张翀宇持有生物控股 39.00%股 | | 物控股有限公 | 122,304,000 | 11.00% | 权，张竞持有生物控股 51.93% | | 司 | | | 股权，张翀宇与张竞系 ...

Core Viewpoint - The major shareholder of the company, Inner Mongolia Jinyu Biological Holdings Co., Ltd., plans to increase its stake in the company by purchasing additional A-shares through the Shanghai Stock Exchange from December 24, 2025, to December 23, 2026, with an investment amount ranging from 50 million to 100 million yuan [1] Group 1 - The major shareholder currently holds 122 million shares, accounting for 11.00% of the company's total shares [1] - The planned increase in shareholding does not have a fixed price range, and the funds will come from self-owned and self-raised sources [1] - The major shareholder has committed not to reduce its holdings during the implementation period of the increase and for the statutory period after completion [1]

格隆汇12月23日丨生物股份(600201.SH)公布，基于对公司未来持续稳定发展的信心和长期投资价值的 认可，增强投资者信心，生物控股计划自本公告披露之日起12个月内，通过上海证券交易所系统以集中 竞价方式增持公司股份，增持总金额不低于人民币5000万元，不超过人民币10000万元（以下简称"本次 增持计划"），本次增持计划不设置固定价格、价格区间，生物控股将基于对公司股票价值的合理判 断，并根据公司股票价格波动情况及资本市场整体趋势，择机实施本次增持计划。 ...

格隆汇12月23日丨生物股份(600201.SH)公布，基于对公司未来持续稳定发展的信心和长期投资价值的 认可，增强投资者信心，生物控股计划自本公告披露之日起12个月内，通过上海证券交易所系统以集中 竞价方式增持公司股份，增持总金额不低于人民币5000万元，不超过人民币10000万元（以下简称"本次 增持计划"），本次增持计划不设置固定价格、价格区间，生物控股将基于对公司股票价值的合理判 断，并根据公司股票价格波动情况及资本市场整体趋势，择机实施本次增持计划。 ...

生物股份公告，公司大股东内蒙古金宇生物控股有限公司持股1.22亿股，占11.00%，计划自2025年12月 24日至2026年12月23日通过上海证券交易所集中竞价增持公司A股，增持金额5000万元～1亿元，不设 固定价格区间，资金来源为自有及自筹，并承诺在增持计划实施期间及实施完成后法定期限内不减持所 持股份。 ...

证券之星消息，12月23日动物保健板块较上一交易日上涨0.36%，生物股份领涨。当日上证指数报收于 3919.98，上涨0.07%。深证成指报收于13368.99，上涨0.27%。动物保健板块个股涨跌见下表： 从资金流向上来看，当日动物保健板块主力资金净流出2100.59万元，游资资金净流出1797.28万元，散 户资金净流入3897.87万元。动物保健板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

Core Viewpoint - Junshi Biosciences has submitted its IPO application to the Hong Kong Stock Exchange, aiming to enter the biotech sector with its innovative TIL therapies, GC101 and GC203, which show promising clinical results in treating solid tumors [1] Company Overview - Junshi Biosciences, established six years ago, focuses on innovative cell therapies and drug development for solid tumors [1] - The company has reported cumulative losses exceeding 350 million yuan from 2023 to the first half of 2025, with cash and cash equivalents at 63.635 million yuan as of June 30, 2025 [1][5] Product Pipeline - GC101, a TIL therapy, has shown an objective response rate (ORR) of 41.7% in patients with metastatic non-small cell lung cancer and 30% in advanced melanoma patients, positioning it as a potential first TIL therapy approved in China [1][3] - GC203, the world's first non-viral vector gene-modified TIL therapy, has demonstrated a 33.3% ORR in heavily pre-treated ovarian cancer patients [4] Market Potential - The global TIL therapy market is expected to reach $4.5 billion by 2035, with China's market projected to grow at a compound annual growth rate (CAGR) of 40% from 2030 to 2035, outpacing global growth [4] Financial Challenges - The company has not yet generated product sales revenue and is experiencing increasing R&D expenditures, which reached 57.62 million yuan in 2023 and are projected to rise further [5] - Junshi Biosciences faces significant cash flow pressure due to ongoing losses and rising operational costs [5] Competitive Landscape - The TIL therapy market is highly competitive, with over ten similar therapies in development globally, including Iovance's approved product, Amtagvi [6] - Junshi Biosciences must continue to build advantages in clinical progress, efficacy data, and cost control to stand out in the competitive environment [6] Regulatory Environment - Positive signals from industry policies, such as breakthrough therapy designations and conditional approval processes, are accelerating the approval of innovative cell therapies in China [6]

从资金流向上来看，当日动物保健板块主力资金净流出1.39亿元，游资资金净流入5021.79万元，散户资 金净流入8897.91万元。动物保健板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，12月22日动物保健板块较上一交易日上涨2.22%，生物股份领涨。当日上证指数报收于 3917.36，上涨0.69%。深证成指报收于13332.73，上涨1.47%。动物保健板块个股涨跌见下表： ...

Group 1 - The core point of the news is that Jin Yu Biological Technology Co., Ltd. has seen a stock price increase of 5.01%, reaching 15.72 yuan per share, with a trading volume of 779 million yuan and a turnover rate of 4.53%, resulting in a total market capitalization of 17.477 billion yuan [1] - The company, established on March 13, 1993, and listed on January 15, 1999, primarily engages in the research, production, and sales of veterinary biological products, with main business revenue composition being 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1] Group 2 - From the perspective of major fund holdings, E Fund has one fund heavily invested in Jin Yu Biological, specifically the E Fund CSI Modern Agriculture Theme ETF (562900), which increased its holdings by 19,600 shares in the third quarter, totaling 239,100 shares, accounting for 2.79% of the fund's net value, ranking as the eighth largest holding [2] - The E Fund CSI Modern Agriculture Theme ETF (562900) was established on December 2, 2021, with a latest scale of 826.209 million yuan, showing a year-to-date return of 10.69% and a one-year return of 8.05%, with a cumulative loss of 20.3% since inception [2]